| 27th Feb 2024 6:00 pm |
RNS |
Update to Faron’s Financial Calendar for 2024 |
| 21st Feb 2024 2:00 pm |
RNS |
Continued Negotiations Regarding Events of Default |
| 19th Feb 2024 10:30 am |
RNS |
Events of Default |
| 31st Jan 2024 7:00 am |
RNS |
Further re: Exercise of options |
| 25th Jan 2024 7:00 am |
RNS |
BEXMAB Insights into Patient Profiles |
| 19th Jan 2024 1:00 pm |
RNS |
Exercise of options - Issue of equity |
| 9th Jan 2024 7:00 am |
RNS |
First Patient Dosed in Ph 2 of the BEXMAB Trial |
| 3rd Jan 2024 7:00 am |
RNS |
Presentation at J.P. Morgan Healthcare Conference |
| 22nd Dec 2023 7:00 am |
RNS |
Faron’s Financial Calendar for 2024 |
| 11th Dec 2023 7:00 am |
RNS |
Phase 1 BEXMAB data presented at ASH |
| 7th Dec 2023 7:00 am |
RNS |
MATINS Trial in Cell Reports Medicine |
| 4th Dec 2023 7:00 am |
RNS |
Grant of options |
| 6th Nov 2023 8:13 am |
RNS |
Faron Initiates Phase 2 Part of BEXMAB Study |
| 6th Nov 2023 7:00 am |
RNS |
Faron Initiates Phase 2 Part of BEXMAB Study |
| 2nd Nov 2023 1:00 pm |
RNS |
Faron to present data from BEXMAB study at ASH |
| 27th Oct 2023 1:00 pm |
RNS |
Manager's transactions |
| 27th Oct 2023 7:15 am |
RNS |
Exercise of options |
| 27th Oct 2023 7:00 am |
RNS |
Results of Placing |
| 26th Oct 2023 4:30 pm |
RNS |
Proposed Issue and Placing |
| 11th Oct 2023 7:00 am |
RNS |
Faron Announces Positive BEXMAB Study Update |
| 3rd Oct 2023 7:00 am |
RNS |
Faron to host webcast on new BEXMAB study data |
| 22nd Sep 2023 4:00 pm |
RNS |
Board Changes |
| 22nd Sep 2023 11:00 am |
RNS |
Results of EGM |
| 21st Sep 2023 7:00 am |
RNS |
Faron Appoints Interim Chief Medical Officer |
| 8th Sep 2023 7:00 am |
RNS |
Change in the Board of Directors |
| 6th Sep 2023 7:00 am |
RNS |
Faron to Present at H.C. Wainwright Conference |
| 1st Sep 2023 10:00 am |
RNS |
Notice of EGM |
| 31st Aug 2023 2:00 pm |
RNS |
Exercise of options |
| 29th Aug 2023 7:01 am |
RNS |
Faron 2023 Half-Year Financial Results |
| 29th Aug 2023 7:00 am |
RNS |
FDA Orphan Drug Designation for Bexmarilimab |
| 4th Aug 2023 7:00 am |
RNS |
Notice of Half-Year Financial Results |
| 2nd Aug 2023 7:00 am |
RNS |
Faron to Participate at Canaccord Conference |
| 25th Jul 2023 7:00 am |
RNS |
Grant of Options |
| 19th Jul 2023 7:01 am |
RNS |
Faron to Hold BEXMAB Study Conference Call |
| 19th Jul 2023 7:00 am |
RNS |
BEXMAB study update |
| 30th Jun 2023 4:52 pm |
RNS |
Holding(s) in Company |
| 29th Jun 2023 7:00 am |
RNS |
Announcement of Placing |
| 12th Jun 2023 7:00 am |
RNS |
Exercise of options |
| 9th Jun 2023 8:00 am |
RNS |
New biomarker data from BEXMAB study at EHA2023 |
| 5th Jun 2023 7:00 am |
RNS |
Board Member to Assume Transactional Advisor Role |
